Gepotidacin, a new oral antibiotic that was approved by the Food and Drug Administration in March 2025 for the treatment of female adults and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract infections (UTIs) was found to provide rapid symptom improvement—as early as 24 hours after the first dose—according to results of a clinical trial published in JAMA Network Open. The nonrandomized study enrolled 97 patients at 21 U.S. sites who received gepotidacin …
Read More
